Direct AMPK Activator Compounds for Metabolic Health
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic disorders like type 2 diabetes lack direct and effective AMPK-activating drugs, with existing synthetic activators facing issues of poor oral availability and adverse effects, while natural compounds that indirectly stimulate AMPK have unclear mechanisms and potential side effects.
Innovation Solution
Development of specific compounds, such as Lusianthridin (7-Methoxy-9,10-dihydrophenanthrene-2,5-diol) and other phenanthrene derivatives, which directly activate AMPK by binding to the Allosteric Drug and Metabolic (ADaM) binding site, specifically targeting muscle and liver tissues to improve metabolic health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic AMPK activators are used to directly activate AMPK, then AMPK activation efficacy is improved, but oral availability deteriorates and adverse effects increase
Solution Approach 1:
The patent modifies the chemical structure of AMPK activators by changing molecular parameters (adding specific functional groups, modifying ring structures) to improve oral bioavailability while maintaining AMPK activation efficacy. The compounds of formula I represent a series of structurally modified analogs with optimized pharmacokinetic properties.
Solution Approach 2:
The patent develops a series of small-molecule compounds that can be metabolized and eliminated more readily than long-acting activators, reducing the risk of chronic adverse effects such as cardiac hypertrophy while providing sufficient therapeutic activation.
2Reliability
If strong AMPK activation is achieved, then metabolic health benefits are improved, but cardiac glycogen content and hypertrophy increase
Solution Approach 1:
The patent designs compounds that provide partial AMPK activation sufficient for metabolic benefits without excessive activation that would cause cardiac side effects. The moderate activation level achieves the therapeutic window for treating insulin resistance and type 2 diabetes while avoiding cardiac glycogen accumulation and hypertrophy.
Solution Approach 2:
The patent achieves tissue-selective AMPK activation, with preferential activation in skeletal muscle and liver tissues where it provides metabolic benefits, while minimizing activation in cardiac tissue to avoid adverse effects. This selective action is achieved through the specific molecular structure and binding properties of the compounds.
3Reliability
If natural compounds are used to indirectly stimulate AMPK, then metabolic health benefits are improved, but mechanism clarity and safety deteriorate
Solution Approach 1:
The patent develops compounds that serve as direct intermediaries binding to the AMPK drug-binding site, providing a clear and direct mechanism of action. Unlike indirect natural compounds that may affect multiple targets, these compounds specifically target AMPK, eliminating mechanistic ambiguity while maintaining safety.
4Reliability
If natural compounds are used to indirectly stimulate AMPK, then metabolic health benefits are improved, but side effects increase
Solution Approach 1:
The patent develops compounds with high specificity for the AMPK drug-binding site, acting as precise intermediaries that avoid off-target effects. This specific binding mechanism eliminates the cellular and mitochondrial poisoning effects associated with non-specific natural compounds while preserving beneficial metabolic effects.
Data Source
AI summary
The present invention relates to a compound having general formula I for use in the activation of AMPK. A composition comprising said compound for use in the activation of AMPK is also provided. Said compounds are 9,10 dihydrophenanthrenes, in particular selected from the group consisting of: (i) Lusianthridin i.e. 7-Methoxy-9,10-dihydrophenanthrene-2,5-diol, (ii) 7-Methoxy-9,10-dihydrophenanthrene-2,3,5-triol, (iii) 9,10-dihydrophenanthrene-2,5-diol, (iv) 9,10-Dihydrophenanthrene-2,4,7-triol (v) 9,10-Dihydro-7-methoxy-3,5-phenanthrenediol, and the activation of AMPK improves the condition, disorder, or disease related to cardiometabolic health, obesity, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, and cancer.